ArticleCurrent treatment options in rheumatology2017
An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.
Article in Current treatment options in rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis.Orphanet journal of rare diseases · 2020Pooled it
- Clinical features and the impact of MEFV Variants in pediatric non-infectious uveitis: a retrospective single-center study.Clinical rheumatology · 2026Article
- Clinical characteristics, management, and outcomes of pediatric non-infectious uveitis: A multicenter study in Saudi Arabia.PloS one · 2026Observational
- Biosimilars in Adult and Pediatric Noninfectious Uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Visual Function and Intraocular Pressure Outcomes Following Surgical Intervention in Pediatric Patients with Inflammatory Glaucoma.Ocular immunology and inflammation · 2025Article
- Pediatric peripapillary choroidal neovascularization secondary to ocular sarcoidosis: a long-term follow-up case.BMC ophthalmology · 2025Article
- Uveitis in the Pediatric Population and Therapeutic Management: A Current Literature Review.Children (Basel, Switzerland) · 2024Review
- The Efficacy of Adalimumab in Children with Chronic Non-infectious Posterior Uveitis and Panuveitis: A Retrospective Cohort Study.Ophthalmology and therapy · 2024Article
- Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.Frontiers in ophthalmology · 2024Review
- Efficacy and Safety of Adalimumab in Pediatric Non-infectious Non-anterior Uveitis: Real-life Experience From the International AIDA Network Uveitis Registry.Ophthalmology and therapy · 2023Article
- Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis.Acta ophthalmologica · 2022Article
- Article
- Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022Review
- Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.Annals of eye science · 2021Article
- A review of ocular adverse events of biological anti-TNF drugs.Journal of ophthalmic inflammation and infection · 2020Review
- JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.Clinical rheumatology · 2020Article
- New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview.Frontiers in pharmacology · 2020Review
- Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis.Pediatric rheumatology online journal · 2019Article
- Etiologic Spectrum and Follow-Up Results of Noninfectious Uveitis in Children: A Single Referral Center Experience.Archives of rheumatology · 2019Article
- Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis.Journal of ophthalmic inflammation and infection · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
There are no standardized treatment protocols for pediatric non-infectious uveitis. Topical corticosteroids are the typical first-line agent, although systemic corticosteroids are used in intermediate, posterior and panuveitic uveitis. Corticosteroids are not considered to be long-term therapy due to potential ocular and systemic side effects. In children with severe and/or refractory uveitis, timely management with higher dose disease-modifying antirheumatic drugs (DMARDs) and biologic agents is important. Increased doses earlier in the disease course may lead to improved disease control and better visual outcomes. In general, methotrexate is the usual first-line steroid-sparing agent and given as a subcutaneous weekly injection at >0.5 mg/kg/dose or 10-15 mg/m2 due to better bioavailability. Other DMARDs, for instance mycophenolate, azathioprine, and cyclosporine are less common treatments for pediatric uveitis. Anti-tumor necrosis factor-alpha agents, primarily infliximab and adalimumab are used as second line agents in children refractory to methotrexate, or as first-line treatment in those with severe complicated disease at presentation. Infliximab may be given at a minimum of 7.5 mg/kg/dose every 4 weeks after loading doses, up to 20 mg/kg/dose. Adalimumab may be given up to 20 or 40 mg weekly. In children who fail anti-tumor necrosis factor-alpha agents, develop anti-tumor necrosis factor-alpha antibodies, experience adverse effects, or have difficulty with tolerance, there is less data available regarding subsequent treatment. Promising results have been noted with tocilizumab infusions every 2-4 weeks, abatacept monthly infusions and rituximab.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.